<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Audouard E</submitter><funding>Horizon 2020</funding><pagination>994-1008</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9733677</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>352</volume><pubmed_abstract>Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based </pubmed_abstract><journal>Journal of controlled release : official journal of the Controlled Release Society</journal><pubmed_title>Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis.</pubmed_title><pmcid>PMC9733677</pmcid><funding_grant_id>720694</funding_grant_id><pubmed_authors>Buchmann P</pubmed_authors><pubmed_authors>Florea M</pubmed_authors><pubmed_authors>Khel A</pubmed_authors><pubmed_authors>Rousselot L</pubmed_authors><pubmed_authors>Escudero E</pubmed_authors><pubmed_authors>Audouard E</pubmed_authors><pubmed_authors>Dufayet-Chauffaut G</pubmed_authors><pubmed_authors>Cartier N</pubmed_authors><pubmed_authors>Michel F</pubmed_authors><pubmed_authors>Folcher M</pubmed_authors><pubmed_authors>Kim T</pubmed_authors><pubmed_authors>Piguet F</pubmed_authors><pubmed_authors>Pierroz V</pubmed_authors><pubmed_authors>Altynbekova K</pubmed_authors><pubmed_authors>Delgaldo C</pubmed_authors><pubmed_authors>Gillet-Legrand B</pubmed_authors><pubmed_authors>Soler ABA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis.</name><description>Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-05-28T02:52:07.257Z</modification><creation>2024-11-12T10:54:55.498Z</creation></dates><accession>S-EPMC9733677</accession><cross_references><pubmed>36370877</pubmed><doi>10.1016/j.jconrel.2022.11.008</doi></cross_references></HashMap>